GlassScriptPhysician profile
Katelyn Mcglaughlin
NPI 1366295552
$4,771.19
in general payments reported to CMS, 2019-2025
42 companies · $3,294 in 2025
The $3,294 reported for 2025 was more than what 97% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,477 · 2025: $3,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,597 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,597.20 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $446.67 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $429.96 | 2024-2025 | Enhertu, Imfinzi, Calquence |
| Pfizer INC. | $358.54 | 2024-2025 | |
| Janssen Biotech, INC. | $350.32 | 2024-2025 | Tecvayli, Rybrevant, Darzalex |
| Daiichi Sankyo INC. | $347.11 | 2024-2025 | Enhertu, Datroway |
| Incyte Corporation | $268.61 | 2024-2025 | Jakafi, Monjuvi, Niktimvo |
| Takeda Pharmaceuticals U.S.A., INC. | $199.34 | 2024-2025 | Ninlaro, Fruzaqla, Alunbrig |
| E.R. Squibb & Sons, L.L.C. | $179.67 | 2025 | Opdivo, Opdualag |
| Sumitomo Pharma America, INC. | $169.81 | 2024-2025 | Orgovyx |
| Beone Medicines USA, INC. | $148.50 | 2025 | Brukinsa, Tevimbra |
| Bayer Healthcare Pharmaceuticals INC. | $141.08 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $127.62 | 2024-2025 | |
| Celgene Corporation | $125.52 | 2024-2025 | Reblozyl, Opdualag |
| Abbvie INC. | $112.24 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $104.19 | 2025 | Provenge |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $99.23 | 2024-2025 | Ultomiris |
| Genzyme Corporation | $81.69 | 2025 | |
| Jazz Pharmaceuticals INC. | $78.76 | 2024-2025 | |
| Glaxosmithkline, LLC. | $78.41 | 2024-2025 | Ojjaara |
| Sobi, INC | $77.96 | 2024-2025 | |
| Gilead Sciences, INC. | $71.73 | 2024-2025 | Trodelvy |
| Ipsen Biopharmaceuticals, INC | $70.34 | 2024-2025 | Onivyde |
| Puma Biotechnology, INC. | $65.93 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $58.40 | 2024-2025 | Monoferric, Cosela |
| Stemline Therapeutics INC. | $56.78 | 2025 | Orserdu |
| Agios Pharmaceuticals, INC. | $53.25 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.80 | 2025 | |
| Iovance Biotherapeutics, INC. | $42.58 | 2025 | Amtagvi |
| Genmab U.S., INC. | $42.14 | 2024 | Epkinly |
| Exelixis INC. | $38.18 | 2024 | Cabometyx |
| Array Biopharma INC | $34.81 | 2024 | Braftovi, Tukysa, Mektovi |
| Eisai INC. | $32.74 | 2025 | |
| Blueprint Medicines Corporation | $27.11 | 2024 | Ayvakit |
| Geron Corporation | $27.04 | 2025 | Rytelo |
| Adc Therapeutics America, INC. | $25.98 | 2025 | |
| Lilly USA, LLC | $24.67 | 2025 | Verzenio, Jaypirca |
| Legend Biotech USA INC. | $23.90 | 2024 | |
| Beigene USA, INC. | $22.86 | 2025 | Brukinsa |
| Emd Serono, INC. | $22.81 | 2025 | |
| Genentech USA, INC. | $19.98 | 2025 | Polivy, Lunsumio, Tecentriq |
| Recordati_rare_diseases_inc. | $17.59 | 2025 | Sylvant |
| Astellas Pharma US INC | $17.34 | 2025 | Padcev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Mcglaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.